Noble Metals in Medicinal Inorganic Chemistry

Dear Colleagues,

The study and development of noble metal-based drugs is a promising approach to designing new drugs for treating several diseases. Cisplatin and other platinum-based compounds are powerful chemotherapeutic agents used currently in the clinical treatment of cancer. The chemical and biological properties of coordination and organometallic compounds have allowed the design of new metallodrugs that include different metal ions. Ruthenium-based compounds have seen advanced clinical trials as potential novel anticancer drugs. Gold-based drugs are currently used in the clinic for the treatment of rheumatoid arthritis. These metal ions and rhodium, iridium, palladium, osmium, and other denominated noble elements have been the subject of study of several investigations due to their interesting pharmacological properties; therefore, it is relevant to the development of novel metal compounds with highlighted pharmacological properties, such as anticancer, antirheumatic, antimalarial, antibacterial, antiparasitic, antifungal, and antiviral drugs.

In this Special Issue, we wish to cover the most recent advances in the development of noble metals in medicinal inorganic chemistry by hosting a mix of original research articles and reviews.

Dr. Esteban Rodríguez-Arce
Prof. Dr. Dinorah Gambino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Inorganics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• metallodrugs
• bioactive noble metals
• medicinal inorganic chemistry
• coordination and organometallic compounds
• biological studies
• mechanism of action
• pharmacological properties

Title: synthesis, characterization, and biological evaluation of a new metal compound as a potential antiparasitic agent
Authors: Dinorah Gambino; Esteban Rodríguez-Arce
Affiliation: Área Química Inorgánica, Facultad de Química, Universidad de la República, Montevideo 11800, Uruguay; Departamento de Química Inorgánica y Analítica, Universidad de Chile, Casilla 233, Santiago, Chile
Abstract: The topic would be focused on developing a new Noble Metal compound with activity against Trypanosomatid parasites which cause Neglected Tropical diseases.

Title: Synthesis, Characterization, DNA, Fluorescence, Molecular Docking, and antimicrobial evaluation of novel Pd(II) Complex Containing O, S donor Schiff base ligand and Azole Derivative
Authors: Maged S. Al-Fakeh; Muneera Alrasheedi.; Ard elshifa M.E. Mohammed; Sadeq M. Al-Hazmy; Ahmed B.M. Ibrahim; Ibrahim Alhagri; Sabri Messaoudi
Affiliation: Chemistry Department, College of Science, Qassim University, Buraidah 51452, Saudi Arabia
Abstract: Pd(II) with Schiff base ligand 2-Hydroxy-3-Methoxy Benzaldehyde-Thiosemicarbazone (HMBATSC) (L2) and 2-aminobenzothiazole (2-ABZ) (L1) were synthesized. The Schiff base ligand and the Palladium(II) complex were characterized by C.H.N.S, FT-IR, conductance studies, magnetic susceptibility, XRD, and (TGA). The low molar conductance value indicates that the complex are non-electrolytes. The coordination number of the Pd(II) complex is four with square planar geometry. From the elemental analysis and spectral data, the complex was proposed to have the formula [Pd(HMBATSC)(2-ABZ)H2O]. The interaction between the Pd(II) complex and DNA was examined through various methods, including UV-vis spectroscopy, fluorescence techniques, and DNA viscosity titrations. The findings provided strong evidence that the interaction between the Pd(II) complex and DNA occurs through intercalation mode. To investigate the quenching effect, the fluorescence intensity of DNA bound to ethidium bromide (EB) in the presence of the Pd(II) complex was analyzed. The analysis yielded the following values: the Stern-Volmer quenching constant (Ksv) of 1.67 x 104 M-1, the quenching rate constant (kq) of 8.35 × 1011 M-1 s-1, the binding constant (Kb) of 5.20x105 M-1, and the number of binding the sites (n) of 1.392. DFT studies suggest that the azole derivative may act as an electron donor through the pyridine nitrogen, while the shiff base ligand may act as an electron donor via the oxygen and sulfur atoms. TDDFT calculations indicate that intramolecular charge transfer from the shiff base to Pd(II) is responsible for the complex's fluorescence quenching. The powder X-ray diffraction data revealed that the complex is arranged in a monoclinic system. The resulting Pd(II) complex was investigated for its antimicrobial activity and demonstrated antibacterial efficiency. Interestingly, it showed potent activity against E. coli and E. niger that were found to be more powerful than those recorded for Neomycin.